Nivolumab in severe sepsis or septic shock

Phase 1, randomised, double-blind trial of nivolumab in sepsis and septic shock (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Incidence Rates of Serious Adverse Events (SAEs), Adverse Events (AEs), Immune-mediated AEs, AEs Leading to Discontinuation, and Deaths at 90 days, Composite of Vital Signs and Electrocardiogram (ECG) at 90 days and 8 more. Started Dec 2016; status: completed.